Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment

Journal of the National Cancer Institute

Volumn 106, Issue 3, 2014, Pages

  Eriksson, Emma ^a   Wickström, Malin ^b   Perup, Lova Segerström ^b   Johnsen, John I ^b   Eksborg, Staffan ^b   Kogner, Per ^b   Sävendahl, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HUMANIN; PROTEASOME; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; BONE DISEASE; BONE GROWTH; BONE GROWTH IMPAIRMENT; CANCER CELL CULTURE; CANCER GROWTH; CANCER THERAPY; CARTILAGE CELL; CONTROLLED STUDY; EMBRYO; GROWTH; GROWTH DISORDER; GROWTH PLATE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDULLOBLASTOMA; METATARSAL BONE; MOUSE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT; ANIMAL; BONE DEVELOPMENT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMUR; NUDE MOUSE; TIME; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE DEVELOPMENT; BORONIC ACIDS; CELL LINE, TUMOR; CHONDROCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMUR; GROWTH PLATE; HETEROGRAFTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEDULLOBLASTOMA; METATARSAL BONES; MICE; MICE, NUDE; NEUROBLASTOMA; PROTEASOME INHIBITORS; PYRAZINES; TIME FACTORS;

EID: 84898750101     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt459     Document Type: Article

References (59)

1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572-1582.
2. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin. 2004;54(4):208-236.
3. Robson H, Anderson E, Eden OB, et al. Chemotherapeutic agents used in the treatment of childhood malignancies have direct effects on growth plate chondrocyte proliferation. J Endocrinol. 1998;157(2):225-235.
4. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28(15):2625-2634.
5. Mackie EJ, Ahmed YA, Tatarczuch L, et al. Endochondral ossification: how cartilage is converted into bone in the developing skeleton. Int J Biochem Cell Biol. 2008;40(1):46-62.
6. Olsen BR, Reginato AM, Wang W. Bone development. Annu Rev Cell Dev Biol. 2000;16:191-220.
7. Schriock EA, Schell MJ, Carter M, et al. Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol. 1991;9(3):400-405.
8. Thun-Hohenstein L, Frisch H, Schuster E. Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma. Horm Res. 1992;37(3):91-95.
9. Caruso-Nicoletti M, Mancuso M, Spadaro G, et al. Growth and growth hormone in children during and after therapy for acute lymphoblastic leukaemia. Eur J Pediatr. 1993;152(9):730-733.
10. Kirk JA, Raghupathy P, Stevens MM, et al. Growth failure and growthhormone deficiency after treatment for acute lymphoblastic leukaemia. Lancet. 1987;1(8526):190-193.
11. Johnsen JI, Kogner P, Albihn A, et al. Embryonal neural tumours and cell death. Apoptosis. 2009;14(4):424-438.
12. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630-639.
13. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82(2):373-428.
14. Hershko A. Lessons from the discovery of the ubiquitin system. Trends Biochem Sci. 1996;21(11):445-449.
15. Kane RC, Bross PF, Farrell AT, et al. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508-513.
16. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13(18):5291-5294.
17. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4(5):349-360.
18. Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012;120(2):285-290.
19. Brignole C, Marimpietri D, Pastorino F, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst. 2006;98(16):1142-1157.
20. Michaelis M, Fichtner I, Behrens D, et al. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol. 2006;28(2):439-446.
21. Taniguchi E, Cho MJ, Arenkiel BR, et al. Bortezomib reverses a posttranslational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. Pediatr Blood Cancer. 2009;53(2):136-144.
22. Yang F, Jove V, Chang S, et al. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-kB signaling, and synergizes with an ERK inhibitor. Cancer Biol Ther. 2012;13(6):349-357.
23. Soldatenkov VA, Dritschilo A. Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Cancer Res. 1997;57(18):3881-3885.
24. Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004;22(23):4804-4809.
25. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254-259.
26. Muscal JA, Thompson PA, Horton TM, et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013;60(3):390-395.
27. Wu S, De Luca F. Inhibition of the proteasomal function in chondrocytes down-regulates growth plate chondrogenesis and longitudinal bone growth. Endocrinology. 2006;147(8):3761-3768.
28. Zaman F, Menendez-Benito V, Eriksson E, et al. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. Cancer Res. 2007;67(20):10078-10086.
29. Zaman F, Fadeel B, Savendahl L. Proteasome inhibition therapies in childhood cancer. Leukemia. 2008;22(4):883-884; author reply 4-5.
30. Eriksson E, Zaman F, Chrysis D, et al. Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. PLoS One. 2012;7(11):e50523.
31. Hashimoto Y, Niikura T, Tajima H, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A. 2001;98(11):6336-6341.
32. Miao J, Zhang W, Yin R, et al. S14G-Humanin ameliorates Abeta25-35- induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in mice. Neuropeptides. 2008;42(5-6):557-567.
33. Lue Y, Swerdloff R, Liu Q, et al. Opposing roles of insulin-like growth factor binding protein 3 and humanin in the regulation of testicular germ cell apoptosis. Endocrinology. 2010;151(1):350-357.
34. Hoang PT, Park P, Cobb LJ, et al. The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice. Metabolism. 2010;59(3):343-349.
35. Kariya S, Takahashi N, Hirano M, et al. Humanin improves impaired metabolic activity and prolongs survival of serum-deprived human lymphocytes. Mol Cell Biochem. 2003;254(1-2):83-89.
36. Hashimoto Y, Kurita M, Aiso S, et al. Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130. Mol Biol Cell. 2009;20(12):2864-2873.
37. Muzumdar RH, Huffman DM, Atzmon G, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009;4(7):e6334.
38. Xu X, Chua CC, Gao J, et al. Humanin is a novel neuroprotective agent against stroke. Stroke. 2006;37(10):2613-2619.
39. Oh YK, Bachar AR, Zacharias DG, et al. Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice. Atherosclerosis. 2011;219(1):65-73.
40. Guo B, Zhai D, Cabezas E, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003;423(6938):456-461.
41. Zhai D, Luciano F, Zhu X, et al. Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak. J Biol Chem. 2005;280(16):15815- 15824.
42. Luciano F, Zhai D, Zhu X, et al. Cytoprotective peptide humanin binds and inhibits proapoptotic Bcl-2/Bax family protein BimEL. J Biol Chem. 2005;280(16):15825-15835.
43. Aubin JE, Heersche JN, Merrilees MJ, et al. Isolation of bone cell clones with differences in growth, hormone responses, and extracellular matrix production. J Cell Biol. 1982;92(2):452-461.
44. Lunstrum GP, Keene DR, Weksler NB, et al. Chondrocyte differentiation in a rat mesenchymal cell line. J Histochem Cytochem. 1999;47(1):1-6.
45. Johnsen JI, Segerstrom L, Orrego A, et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene. 2008;27(20):2910-2922.
46. Grossman SA, Carson KA, Phuphanich S, et al. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro Oncol. 2008;10(4):608-616.
47. Hanaka H, Pawelzik SC, Johnsen JI, et al. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci U S A. 2009;106(44):18757-18762.
48. Gullbo J, Fryknas M, Rickardson L, et al. Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment. Biochem Pharmacol. 2011;82(2):139-147.
49. Martensson K, Chrysis D, Savendahl L. Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res. 2004;19(11):1805-1812.
50. Segerstrom L, Baryawno N, Sveinbjornsson B, et al. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer. 2011;129(12):2958-2965.
51. Hamner JB, Dickson PV, Sims TL, et al. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery. 2007;142(2):185-191.
52. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50(1):37-45.
53. Gleissman H, Yang R, Martinod K, et al. Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J. 2010;24(3):906-915.
54. Lee C, Raffaghello L, Longo VD. Starvation, detoxification, and multidrug resistance in cancer therapy. Drug Resist Updat. 2012;15(1-2):114-122.
55. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659-661.
56. Demetrius L. Of mice and men. When it comes to studying ageing and the means to slow it down, mice are not just small humans. EMBO Rep. 2005;6(Spec No):S39-S44.
57. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62(17):4996-5000.
58. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest. 2004;22(2):304-311.
59. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004;18(14):14-21.